コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 urrent with MOG antibodies, and 5 (10%) were seronegative.
2 omparable to those of subjects who were Ad26 seronegative.
3 hether the subjects were CMV seropositive or seronegative.
4 who were HPV16 E6 seropositive compared with seronegative.
5 t of whose baseline samples were found to be seronegative.
6 and by 3 months post-infection the bats are seronegative.
7 93 cases were seropositive and 67 cases were seronegative.
8 ease for individuals who are vaccinated when seronegative.
9 for the seropositives and 11.1 years for the seronegatives.
10 Chagas cardiomyopathy, and among 488 T cruzi seronegatives, 24 (5%) had cardiomyopathy, for an incide
15 overall prevalence was 42%, with 28% in HIV-seronegative adults and 71% in HIV-seropositive adults (
17 Dec 10, 2010, and June 25, 2011, 11 897 HIV-seronegative adults were enrolled in SHIMS and 11 232 (9
20 ately to highly restricted in replication in seronegative adults; we sought to determine the biologic
23 galovirus (CMV)-seronegative donor for a CMV-seronegative allogeneic hematopoietic stem cell transpla
24 of 8.3 years (range, 0-26 years), 117 (45%) seronegative and 219 (67%) seropositive patients died.
26 nts (PHIP) were enrolled, as well as 26 HCMV-seronegative and 39 HCMV-seropositive healthy controls.
27 HIV-1 envelop (Env) vaccine in baseline Ad26-seronegative and Ad26-seropositive healthy volunteers.
29 -seronegative pregnant women, as well as CMV-seronegative and CMV-seropositive healthy adults, were i
30 healthy adult volunteers who were previously seronegative and experimentally infected with seasonal i
31 viral therapy who were HSV-2 seropositive or seronegative and HIV-uninfected controls were analyzed b
38 ll TDF IVR-treated macaques (n = 6) remained seronegative and simian-HIV RNA negative after 16 weekly
41 One year after MMR3 receipt, no subject was seronegative, and 10 of 617 (1.6%) had low neutralizing
42 nth after MMR3 receipt, 1 subject (0.2%) was seronegative, and 6 (0.9%) had low neutralizing antibodi
43 more likely to be HPyV9-seropositive but MCV-seronegative, and HPyV7 seropositivity was associated wi
45 total of 2,139 HBsAg-seropositive, anti-HCV-seronegative, and treatment-naive participants without l
47 als immunized with the empty Ad5 vector, Ad5-seronegative animals immunized with the Ad5 SIV vaccine,
48 immunized with the Ad5 SIV vaccine, and Ad5-seronegative animals immunized with the empty Ad5 vector
51 in a G1P[8] rotavirus vaccine trial who were seronegative at baseline, anti-rotavirus immunoglobulin
55 ); in recipients who were Epstein-Barr virus-seronegative at the time of transplant and at risk of pr
56 active IVDU donor who was hepatitis C virus seronegative at time of donation, but was found to be vi
59 1-year follow-up among patients who were HEV seronegative before transplantation, giving an annual in
61 ared with HIV-infected subjects who were HCV seronegative, both HCV viremic and HCV aviremic individu
65 ivity increased PPV to 100% but excluded all seronegative cases (approximately 15% of all RA cases).
66 a subgroup of seropositive-like cases within seronegative cases (PBUHMBOX = 0.008; 2,406 seronegative
68 cluded in the differential diagnosis even in seronegative cases, although it is not typical for hydat
70 om an added gene was previously evaluated in seronegative children as a bivalent intranasal RSV/HPIV3
71 was previously shown to be well tolerated by seronegative children but was insufficiently immunogenic
77 pants contributed 20 477 visits and 2808 HIV-seronegative control participants contributed 27 409 vis
79 280 KSHV-seropositive controls, and 576 KSHV-seronegative controls composing discovery and validation
80 g follow-up and 464 individually matched HIV-seronegative controls were selected from 5 cohorts of wo
81 ted with reduced HIV-1 acquisition among HIV-seronegative controls with high but not low HIV-1 exposu
87 -14, and 15-22 months of age, the proportion seronegative decreased from 8.5% to 3.2%, 2.4%, and 1.5%
88 k is greatest in seropositive recipient (R+)/seronegative donor (D-) transplants and is exacerbated b
90 stimulation in vitro or engineered from HCV-seronegative donor T cells by transduction of a lentivir
91 ecipients who underwent allograft from a CMV-seronegative donor, cases of CMV seropositivity of the d
92 higher risk of chronic GVHD than those with seronegative donors (40.8% v 31.0%, respectively; P < .0
93 val as patients who received grafts from EBV-seronegative donors (hazard ratio [HR], 1.05; 95% CI, 0.
95 ubjects differed significantly from those of seronegative donors for all 3 immunodominant proteins, G
96 om 439 subjects in Jamaica, including HTLV-I-seronegative donors, ACs, and ATL and HAM/TSP patients.
98 .92; 95% CI, .86-.98; P < .01) compared with seronegative donors, if they had received myeloablative
99 al [CI], 1.06-1.21; P < .0001) compared with seronegative donors, whereas no difference was seen in p
104 mes of autoantibody-positive individuals and seronegative FDRs clustered together but separate from t
105 Furthermore, subjects with autoantibodies, seronegative FDRs, and new-onset patients had different
107 re, 0 [range, 0-5]; P = .007), patients with seronegative findings (n = 28) (median visual score, 1.0
110 iated with subclinical infection in children seronegative for DENV at enrollment, for whom a second-d
113 d volunteers aged at least 45 years who were seronegative for HIV-1 from the established Ugandan Gene
117 1767), healthy African girls and young women seronegative for human immunodeficiency virus (HIV) were
118 Of 662 subjects at baseline, 1 (0.2%) was seronegative for MeV-neutralizing antibodies (level, <8
119 Of the 107 serum pairs from infants who were seronegative for RV IgA at enrollment, we observed a str
123 N9) virus hemagglutinins (HAs) despite being seronegative for these viruses in standard hemagglutinat
125 samples from enrolled subjects who remained seronegative from both the placebo and active treatment
126 ean concentrations (GMCs) and the proportion seronegative (GMC <150 mIU/mL) were derived by age at fi
127 y number = 5.93, range = 1.85-9.21) than the seronegative group (mean log copy number = 2.41, range =
129 ences between HTLV-1-seropositive and HTLV-1-seronegative groups were apparent in childhood presentat
132 stvaccination and higher in human CMV (HCMV)-seronegative (HCMV(-)) individuals than in HCMV-seroposi
133 cohort of HIV-infected subjects who were HCV seronegative, HCV viremic (detectable HCV RNA), or HCV a
134 two and 28 urine samples from confirmed and seronegative healthy human subjects, respectively were i
135 HSV-1/HSV-2-seropositive individuals and 47 seronegative healthy individuals (negative controls).
140 resistance to HIV-1 infection in HIV-exposed seronegative (HESN) individuals is suggested to be assoc
141 ates of resistance to HIV-1 in HIV-1-exposed seronegative (HESN) individuals with consistently high e
143 gest cohort of patients treated during acute seronegative HIV infection (AHI) in whom RCI has been st
144 occur both with PrEP initiation during acute seronegative HIV infection and in PrEP breakthrough infe
146 nyan female sex workers (FSWs) (n = 20), HIV-seronegative (HIV-) FSWs (n = 17), and HIV(-) lower-risk
149 HIV-infected women who were HPV DNA and HPV seronegative, immune responses to HPV vaccination were g
150 donation and age-, sex-, and period-matched seronegatives in 1996 to 2002 in the Brazilian cities of
152 the infectiousness of HIV-seropositive and -seronegative index cases have been performed in sub-Saha
153 -B40 group was a risk factor for PTLD in EBV-seronegative individuals (OR = 8.38, 95% CI = 2.18-32.3)
155 censed dengue vaccine that failed to protect seronegative individuals from breakthrough or enhanced d
156 unningham virus DNA was detected in urine of seronegative individuals in a research-grade assay.
157 (PrEP) by human immunodeficiency virus (HIV)-seronegative individuals reduces the risk of acquiring H
164 on in a prospective study of 406 HSV-2/HIV-1-seronegative Kenyan women, of whom 164 acquired HSV-2.
165 ytomegalovirus (CMV)-specific T cells in CMV-seronegative kidney transplant recipients (KTRs) have be
169 bine-tenofovir disoproxil fumarate among HIV-seronegative men and transgender women who have sex with
170 ive (iPrEx) study randomly assigned 2499 HIV-seronegative men and transgender women who have sex with
173 tistically between baseline seropositive and seronegative men at any study visit or over the follow-u
176 e report the effect of FTC/TDF on BMD in HIV-seronegative men who have sex with men and in transgende
180 in classifying atypical multiple sclerosis, seronegative neuromyelitis optica spectrum disorders and
184 both appropriate control samples and defined seronegative NMOSD samples is essential to evaluate thes
188 significantly higher risk for all other EBV seronegative organ transplant groups and also for EBV se
191 We compared (1) HCV-seropositive with HCV-seronegative participants and (2) HCV-viremic with succe
192 ce antigen (HBsAg)-seropositive and anti-HCV-seronegative participants from the Risk Evaluation of Vi
193 tocol analysis at month 7, 100% of initially seronegative participants in the vaccine group were sero
194 ropositive and incidence density-matched HCV-seronegative participants of the Swiss HIV Cohort Study
195 e changes between HCV seroconverters and HCV-seronegative participants while adjusting for baseline c
200 ouples in which HIV-1 was transmitted to the seronegative partner during the study; control couples (
204 We present the case of a 26-year-old HIV-seronegative patient with XDR pulmonary tuberculosis ref
207 of reperfusion compared with cytomegalovirus-seronegative patients (-192 versus -63 cells/muL; P=0.00
208 primary infection occurred in 27 of 43 (63%) seronegative patients and reactivation/reinfection in 28
209 ulosis cases may be less infectious than HIV-seronegative patients only when they are smear-negative
214 7+) = 0.1, 95% CI = 0.02-1.0), whereas E6/E7 seronegative patients with evidence of HPV in tumor DNA
217 nrolled HIV-negative and human herpesvirus-8-seronegative patients with symptomatic multicentric Cast
218 the infectiousness of HIV-seropositive and -seronegative patients with tuberculosis to their househo
228 HSV-specific CD4 T cells recovered from HSV-seronegative persons can be explained, in part, by such
231 he intestinal mucosal barrier already in the seronegative phase of acute HIV infection, thereby induc
235 V-associated sequelae occurred in four rhCMV-seronegative pregnant macaques that were CD4(+) T-cell d
244 Early-onset disease was associated with EBV-seronegative recipient status, EBV-positive histology, a
245 2 HHV8-mismatch patients (seropositive donor/seronegative recipient) developed a primary infection, o
247 orted by the increased PCN risk in young EBV seronegative recipients and the presence of EBV in tumor
249 ght seropositive recipients and one of three seronegative recipients displayed peripheral blood CD8+
252 ipients of kidney transplants, including 168 seronegative recipients receiving organs from seropositi
256 years, we observed (HCV seropositive and HCV seronegative, respectively) 107 and 18 liver events, 41
257 -74) in HRP-IIIgG3-seropositive and SE36IgG1-seronegative responders compared with HRP-IIIgG3-seroneg
259 derly individuals, and occasionally leads to seronegative rheumatoid arthritis-like pathologies.
260 clusion chromatography, we obtained from HCV-seronegative sera a purified fraction enriched in inhibi
262 suggesting a major prevention benefit among seronegative sex partners in stable or casual relationsh
264 , panuveitis, severe uveitis associated with seronegative spondyloarthropathy, and scleritis in patie
265 ney transplant recipients between 43 CMV IgG-seronegative (sR(-)) and 86 CMV IgG-seropositive (sR(+))
266 riables associated with DNAemia included EBV seronegative status at transplant (p = 0.045), non-White
267 ndividuals with highly exposed, persistently seronegative status can neutralize infection and present
269 gher for CMV-seropositive as compared to CMV-seronegative subjects and was marginally associated with
273 HIV-1-specific T-cell responses in exposed seronegative subjects suggest that a viral breach of the
275 cords and compared among 32 HIV-infected CMV-seronegative subjects, 126 age, CD4 and gender-matched H
276 (ILCs) was similar to that observed in HIV-1-seronegative subjects, and transcription of genes encodi
282 More specimens from the ART-96W group were seronegative than from the ART-Def group by enzyme immun
283 which HIV-1-susceptible partners were HSV-2 seronegative to estimate the effect of acyclovir on risk
284 6/11/16/18/31/33/35/39/45/51/52/56/58/59 and seronegative to HPV 6/11/16/18 at day 1, and had a norma
285 patients and control group participants were seronegative to IgA antibodies to TG2, endomysium, and d
286 at the seroconversion visit, six (18%) of 33 seronegative transgender women (p=0.31), and 58 (52%) of
287 household contacts of HIV-seropositive and -seronegative tuberculosis cases (relative risk, 0.89; 95
288 proteins and was recently shown to induce in seronegative volunteers a CD4 T cell response largely do
289 ormalities associated with HPV-16/18 between seronegative vs seropositive women (15-25 years) in the
290 hazard ratio (HR) for PTLD if recipient EBV seronegative was 5.005 for KTX, 6.528 for HTX and 2.615
291 SCT patients, 29 349 seropositive and 20 193 seronegative, were identified from the European Group fo
292 re seen in patients when they became MOG-IgG seronegative, whereas a persistent positive serological
293 humans, even though the study subjects were seronegative with respect to the vaccine viruses before
296 ually randomized superiority trial among HIV-seronegative women at three sites in Malawi with high SP
297 ble genital HIV RNA varied from 73% in HSV-2 seronegative women to 94% in women with herpetic lesions
299 f the general population of HSV-1- and HSV-2-seronegative women, the investigational vaccine was effe
301 ort-term renal safety of TDF/FTC PrEP in HIV-seronegative young men and suggest that endocrine disrup
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。